Erratum: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)

Jurij Hanzel, Erwin Dreesen, Séverine Vermeire, Mark Löwenberg, Frank Hoentjen, Peter Bossuyt, Esmé Clasquin, Filip J. Baert, Geert R. D'Haens, Ron Mathôt

Research output: Contribution to JournalComment / Letter to the editorAcademic

Abstract

In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.

Original languageEnglish
Pages (from-to)817
Number of pages1
JournalInflammatory bowel diseases
Volume28
Issue number5
DOIs
Publication statusPublished - 1 May 2022

Cite this